358 related articles for article (PubMed ID: 22755429)
1. Long-term post transplant alloantibody monitoring: a single center experience.
Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A
Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
4. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
5. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
[TBL] [Abstract][Full Text] [Related]
6. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
7. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
[TBL] [Abstract][Full Text] [Related]
8. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
Kimball PM; King A
Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
[TBL] [Abstract][Full Text] [Related]
9. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience.
Mujtaba MA; Fridell JA; Higgins N; Sharfuddin AA; Yaqub MS; Kandula P; Chen J; Mishler DP; Lobashevsky A; Book B; Powelson J; Taber TE
Clin Transplant; 2012; 26(5):E492-9. PubMed ID: 22938159
[TBL] [Abstract][Full Text] [Related]
10. Detailed examination of HLA antibody development on renal allograft failure and function.
Zhu L; Lee PC; Everly MJ; Terasaki PI
Clin Transpl; 2008; ():171-87. PubMed ID: 19711514
[TBL] [Abstract][Full Text] [Related]
11. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
12. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
Everly MJ
Clin Transpl; 2011; ():319-25. PubMed ID: 22755425
[TBL] [Abstract][Full Text] [Related]
13. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation.
Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML
Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991
[TBL] [Abstract][Full Text] [Related]
14. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
15. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
16. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients.
Wu P; Everly MJ; Jin J; Mao Y; Chen J
Clin Transpl; 2011; ():365-8. PubMed ID: 22755432
[TBL] [Abstract][Full Text] [Related]
17. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
[TBL] [Abstract][Full Text] [Related]
18. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
Kanter Berga J; Pallardo Mateu LM; Beltran Catalan S; Puig Alcaraz N; Sancho Calabuig A; Gavela Martinez E; Avila Bernabeu A; Crespo Albiach J
Transplant Proc; 2011; 43(6):2154-6. PubMed ID: 21839219
[TBL] [Abstract][Full Text] [Related]
19. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
20. Annual literature review of donor-specific HLA antibodies after organ transplantation.
Kaneku H
Clin Transpl; 2011; ():311-8. PubMed ID: 22755424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]